All articles tagged with #ceo
Media entrepreneur Byron Allen will acquire a majority stake in BuzzFeed and assume CEO and chair roles, with Jonah Peretti becoming president of BuzzFeed AI; Allen Family Digital will own 52% of shares for about $120 million ($3 per share), funded by cash at close and a five‑year promissory note, as BuzzFeed seeks liquidity, cost cuts, and a path forward amid debt and Nasdaq delisting risk.
Bloomberg reports Apple plans to install John Ternus as CEO on Sept. 1 and quickly market him as the face of a new, $2,000 foldable iPhone rollout, tying his career arc to the product and framing it as the start of a blockbuster new category.
Lululemon has named Heidi O’Neill, a Nike veteran who helped scale Nike’s business, as its next CEO, effective Sept. 8, to accelerate product breakthroughs and deepen the brand’s cultural relevance after a period of slower growth. O’Neill will receive a $1.4 million salary, a target bonus of 200%, about $10 million in equity, plus one-time grants and a $2 million retention bonus, while interim co-CEOs Meghan Frank and André Maestrini remain in the short term. The appointment comes as investors weigh how the company can reset growth after missteps and a decline in market value; shares moved lower after the news.
Disney named Josh D’Amaro, a 28-year veteran who led Disney Experiences, as its next chief executive, making him the ninth CEO in the company’s history. The piece highlights five key aspects of D’Amaro: his ability to connect with people, a hands-on yet delegating leadership style, an emotional reaction to winning the job, a substantial pay package tied to the promotion, and his artistic roots and Georgetown education that shaped his business path.
Target's new chief executive, Michael Fiddelke, says adopting fresh perspectives while reaffirming Target's core values will be central to regaining customer trust, addressing both shoppers and investors at the March 3, 2026 Financial Community Meeting in Minneapolis.
Disney named parks chief Josh D’Amaro its next CEO, succeeding Bob Iger as the company enters a leadership transition.
Disney’s board elected Josh D’Amaro to become Chief Executive Officer, effective March 18, 2026, succeeding Bob Iger; Dana Walden will be President and Chief Creative Officer reporting to him, with Iger as Senior Advisor through 2026. D’Amaro, a 28-year Disney veteran, chairs Disney Experiences and will oversee major expansions and strategic initiatives as part of a formal succession process overseen by the board.
Bob Iger is reportedly planning to step down as Disney’s CEO before his contract ends on December 31, 2026, with the board expected to announce a successor in early 2026; Iger has told associates he wants to reduce daily management and pursue other interests, and he remains up for a one-year reelection to Disney’s board in 2026.
AIG has appointed veteran executive Eric Andersen as its new CEO following a challenging succession process, signaling a strategic move to stabilize and lead the company forward.
Greg Beadles has been promoted to President and CEO of the Atlanta Falcons, bringing over 30 years of experience with the organization, including key roles in stadium development and team operations, and will oversee all business aspects of the team.
Louis Gerstner, who famously revitalized IBM as its CEO and transformed its culture and focus, has died at age 83. His leadership helped steer IBM away from potential bankruptcy towards success, and he was also known for his philanthropy and involvement in public education initiatives.
BP has replaced its CEO Murray Auchincloss after less than two years in the role, signaling a leadership change within the company.
The CEO of iRobot criticized the previous management for being in denial about the company's issues, indicating internal problems that may have affected the company's performance.
Cinven's CEO and CFO are stepping down amid concerns over potential bans related to price gouging practices, highlighting regulatory risks facing the private equity firm.
Doug Ingram of Sarepta Therapeutics is criticized as the worst biopharma CEO of 2025 for making risky decisions to push for broad approval of the gene therapy Elevidys for Duchenne muscular dystrophy, despite limited safety and efficacy data, leading to tragic consequences.